Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Non-Current Assets (2019 - 2025)

Allogene Therapeutics' Non-Current Assets history spans 7 years, with the latest figure at $179.1 million for Q3 2025.

  • For Q3 2025, Non-Current Assets fell 37.11% year-over-year to $179.1 million; the TTM value through Sep 2025 reached $828.7 million, down 2.41%, while the annual FY2024 figure was $245.3 million, 33.53% up from the prior year.
  • Non-Current Assets for Q3 2025 was $179.1 million at Allogene Therapeutics, down from $187.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $579.5 million in Q4 2021 and bottomed at $179.1 million in Q3 2025.
  • The 5-year median for Non-Current Assets is $268.9 million (2023), against an average of $323.3 million.
  • The largest annual shift saw Non-Current Assets surged 151.47% in 2021 before it plummeted 49.48% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $579.5 million in 2021, then tumbled by 49.48% to $292.8 million in 2022, then plummeted by 37.24% to $183.7 million in 2023, then skyrocketed by 33.53% to $245.3 million in 2024, then decreased by 27.01% to $179.1 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Non-Current Assets are $179.1 million (Q3 2025), $187.9 million (Q2 2025), and $216.4 million (Q1 2025).